BJMO - volume 10, issue 4, july 2016
H. Van Poppel MD, PhD
The 13th meeting of the EAU Section of Oncological Urology took place in Warsaw in January 2016. The most important newcomers were the checkpoint inhibitors in metastatic renal cell carcinoma and in bladder cancer. In prostate cancer, early administration of docetaxel in newly diagnosed metastatic prostate cancer was the major practice changing news, next to whole exome and transcriptome sequencing that will become important
(BELG J MED ONCOL 2016;10(4):143–146)
Read moreBJMO - volume 10, issue 3, may 2016
L. Decoster MD, PhD
Report from the 2015 Annual Meeting of the International Society of Geriatric Oncology (SIOG).
The 2015 Annual Conference of the International Society of Geriatric Oncology took place in Prague, Czech Republic from November 12–14th. More than 400 delegates with a special interest in the care for older patients with cancer attended this conference, including medical oncologists, geriatricians, surgeons, nurses and other professional health care workers. The meeting provided an overview of current advances in geriatric oncology domains.
(BELG J MED ONCOL 2016;10(3):108–9)
Read moreBJMO - volume 10, issue 2, april 2016
S. Ward MD, E. Wouter MD, D. De Ridder MD, PhD
21–22 September 2015, Leuven, Belgium
(BELG J MED ONCOL 2016;10(2):76-80)
Read moreBJMO - volume 10, issue 1, february 2016
Tom Feys MBA, MSc
From the 8th till the 12th of December, San Antonio, TX was again transformed into the world’s capital in the fight against breast cancer. The 2015 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) was a joint presentation of the Cancer Therapy & Research Centre at the University of Texas Health Science Centre in San Antonio, the American Association for Cancer Research, and the Baylor College of Medicine. This years’ meeting drew more than 6,000 participants from all over the globe and again proved to be the number one breast cancer meeting in the world. This report will highlight seven key studies presented during the meeting.
(BELG J MED ONCOL 2016;10(1):41–43)
Read moreBJMO - volume 9, issue 6, november 2015
R. van der Voort PhD
With an estimated 1.6 million deaths worldwide annually, lung cancer is the leading cause of cancer death. However, progress is being made in improving the prevention, diagnosis and treatment of this malignancy. At the European Cancer Congress in Vienna, a substantial number of presentations reported encouraging results of early and late phase clinical trials in lung cancer. Below an impression of several of these studies.
(BELG J MED ONCOL 2015;9(:206–11)
Read moreBJMO - volume 9, issue 6, november 2015
K. Papadimitriou MD, PhD, M. Rasschaert MD, PhD, J. Van den Brande MD, M. Peeters MD, PhD
A large body of trials, including large adjuvant phase III trials up to early phase trials was presented during the 2015 European Cancer Congress (ECC). Immunotherapy, was once more in the center of the scientific interest for different types of cancer and settings. This report will focus on some of the key studies presented during the meeting, referring to gastrointestinal cancer.
(BELG J MED ONCOL 2015;9:217–21)
Read moreBJMO - volume 9, issue 6, november 2015
J. Kerger MD
There were very few new interesting and no practice-changing data presented at the 2015 European Cancer Congress, compared to the ASCO Annual Meeting earlier this year. This lack of presentations is most probably due to the upcoming meeting of ESGO (European Society of Gynecologic Oncology), which was held in Nice end of October 2015.
(BELG J MED ONCOL 2015;9:225–28)
Read more
Top
